D&A at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s D&A?
- Trevi Therapeutics, Inc. (TRVI) reported D&A of $34K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s D&A changed year-over-year?
- Trevi Therapeutics, Inc.'s D&A decreased by 8.1% year-over-year, from $37K to $34K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s D&A?
- Over 3 years (2022 to 2025), Trevi Therapeutics, Inc.'s D&A has grown at a 49.6% compound annual growth rate (CAGR), from $43K to $144K.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.